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Interferonsof mouse hepatitis virus (JHMV) replicates primarily within glial cells following
intracranial inoculation of susceptible mice, with relative sparing of neurons. This study demonstrates that
glial cells derived from neural progenitor cells are susceptible to JHMV infection and that treatment of
infected cells with IFN-γ inhibits viral replication in a dose-dependent manner. Although type I IFN
production is muted in JHMV-infected glial cultures, IFN-β is produced following IFN-γ-treatment of JHMV-
infected cells. Also, direct treatment of infected glial cultures with recombinant mouse IFN-α or IFN-β
inhibits viral replication. IFN-γ-mediated control of JHMV replication is dampened in glial cultures derived
from the neural progenitor cells of type I receptor knock-out mice. These data indicate that JHMV is capable
of infecting glial cells generated from neural progenitor cells and that IFN-γ-mediated control of viral
replication is dependent, in part, on type I IFN secretion.
© 2008 Elsevier Inc. All rights reserved.Introduction
Inoculation of the neurotropic JHMV strain of mouse hepatitis virus
(a positive-strand RNA virus and a member of the Coronaviridae family)
into the CNS of susceptible strains of mice results in an acute
encephalomyelitis. The resulting infection is characterized by wide-
spread viral replication in astrocytes, microglia, and oligodendrocytes
with relatively few infected neurons (Buchmeier and Lane, 1999;
Knobler et al., 1981; Parra et al., 1999; Perlmane et al., 1999). JHMV
infection of the CNS induces localized expression of pro-inflammatory
factors that precedes and accompanies the activation and recruitment
of immune cells into the CNS. During the acute disease phase,
infiltrating virus-specific CD8+ T cells control viral replication by two
different effector mechanisms: IFN-γ secretion controls viral replication
in oligodendrocytes, while a perforin-dependent mechanism promotes
viral clearance fromastrocytes andmicroglia (Lin et al.,1997; Parra et al.,
1999). While a robust and effective cell-mediated immune response is
generated in response to JHMV infection, virus persists within the CNS
and is associated with the development of an immune-mediated
demyelinating disease similar to the human demyelinating disease MS.
During this stage, both T cells and macrophages are important iniology & Biochemistry, 3205
92697-3900, USA. Fax: +1 949
l rights reserved.amplifying disease severity by contributing to myelin damage (Cheever
et al., 1949; Perlman et al., 1999).
Stem cells and neural precursors represent attractive sources for
the generation of remyelination-competent cells since they can
readily amplify and differentiate into oligodendrocyte committed
cells (Ben-Hur et al., 1998; Brustle et al., 1999). Stem cell-derived glial
precursors have been shown to myelinate following transplantation
into the myelin-deficient rat (Brustle et al., 1999), and neural
precursor-derived glial-committed progenitors (Ben-Hur et al., 1998;
Keirstead et al., 1999) have been shown to remyelinate following
transplantation into regions of acute experimental demyelination
(Keirstead et al., 1999). More recently, intracerebroventricular or
intrathecal implantation of neural precursors into rodents with EAE,
an autoimmune model of demyelination, resulted in the migration of
transplanted cells into white matter and improved clinical outcome
(Ben-Hur et al., 2003; Pluchino et al., 2003).
While implantation of myelin-competent cells has shown to be
effective in promoting remyelination in animal models of demyelina-
tion initiated by either infiltration of autoreactive lymphocytes or
injury, there is limited information availablewith regards to the ability
of these cells to enhance demyelination resulting from viral infection.
We believe this is an important and clinically relevant question as the
etiology of MS remains enigmatic although viruses have long been
considered potential triggering agents for initiating disease (Gilden,
2005; Olson et al., 2005). Therefore, evaluating potential cell-
replacement strategies for inducing remyelination in viral models of
neurologic disease may yield insight into whether this method of
210 L. Whitman et al. / Virology 384 (2009) 209–215treatment is effective within the CNS in which a persistent virus is
present. With this in mind, we recently demonstrated that surgical
engraftment of glial committed progenitor cells derived from neural
precursors into JHMV-infected mice with established demyelination
resulted in extensive migration accompanied by remyelination and
axonal sparing (Totoiu et al., 2004). Moreover, remyelination was not
associated with dampened T cell infiltration into the CNS as has
recently been reported following NSC transplantation in mice with
EAE (Aharonowiz et al., 2008; Einstein et al., 2006; Hardison et al.,
2006). Having demonstrated that engraftment of glial cells promotes
remyelination following JHMV-induced demyelination, we next were
interested in addressing several interrelated issues including i) if glial
cells derived from neural precursor cells were susceptible to infection
and ii) how infectionmay be controlled within this population of cells.
We believe these are relevant questions within the context of studying
animal models of viral-induced demyelination as cells are being
transplanted into the CNS in which a persistent virus is present.
Therefore, analyzing the susceptibility of cellular progeny derived
from neural precursor cells to viral infection is important in that these
cells may represent important viral reservoirs in the face of persistent
infection. Understanding consequences of infection and how replica-
tion may be controlled within these cells will provide insight into
understanding host defense mechanisms of implanted cells as well as
potential relevance to disease outcome. The relevance of this is further
highlighted by the fact that while previous studies have demonstrated
that JHMV is able to infect and replicate within glial cells (Dubois-
Dalcq et al., 1982; Lavi et al., 1987; Rempel et al., 2005), the fate of
neural progenitor cells as well as cells derived from this population to
viral infection is not well characterized.
In the present study, we demonstrate that primary cultures of glia
derived from neural progenitor cells are susceptible to JHMV infection
and support viral replication. Additionally, while IFN-β production is
dampened in response to viral infection, treatment with recombinantFig. 1.Differentiation of neural progenitor cells. The differentiation potential of striatal neural
in non-adherent growth factor containing media, viewed in phase contrast. Cells were grow
out from clusters within 6 h of plating, and by 2 days, possess complex morphologies. (C) Mu
adherent substrate in the absence of growth factors (Hoechst-positive nuclei is blue). (D) Qu
growth factors indicated that the differentiation protocol yielded ∼70% Galc+ oligod
immunocytochemistry. Data are presented as average±SEM and are representative of results
400× for magnification for (C).mouse IFN-γ inhibits JHMV replication. The IFN-γ-mediated antiviral
effect is dampened in experiments using cells derived from type I IFN
receptor-deficient mice (IFNAR−/−) indicating a role for type I IFN
signaling in limiting JHMV replication in glia-committed progenitor
cells. Therefore, these findings provide, to our knowledge, the first
demonstration that glia-committed cells derived from neural pre-
cursors are susceptible to JHMV infection as well as identify a potential
mechanism responsible for controlling viral replication.
Results
Neural progenitor cell cultures
The in vitro culture of neural progenitor cells dissected from the
striatal region of the brains of day 1 postnatal C57BL/6mice resulted in
the generation of numerous neurospheres (Fig. 1A) (Hardison et al.,
2006; Totoiu et al., 2004). After the mature neurospheres were plated
on an adherent matrix and incubated in growth medium, the majority
of the cells exhibited oligodendrocyte morphology characterized by
extensive arborization (Fig. 1B). Immunocytochemical staining con-
firmed the morphology results indicating that ∼70% of the cells
differentiated into oligodendrocytes (determined by GalC staining)
(Fig. 1C). The remaining cells had differentiated into either astrocytes
(∼25%, GFAP-expression) or neurons (b5%, Map2 staining) (Fig. 1D).
These differentiated neural progenitor cultures were used for the
subsequent studies examining JHMV susceptibility to infection.
JHMV infects and replicates in differentiated neural progenitor
cell cultures
JHMV is able to infect and replicate in differentiated neural
progenitor cultures as demonstrated by increasing viral titers
measured at 12, 24, and 48 h p.i. (Fig. 2A). Immunocytochemistryprecursors can be restricted by culture conditions. (A) Cell cluster after 5 days of growth
n as free-floating clusters, reaching approximately 200 mm in diameter. (B) Cells spread
ltipolar GalC-positive (green) oligodendrocytes were abundant after 7 days of growth on
antification of cell types after 7 days of growth on adherent substrate in the absence of
endrocytes, ∼25% GFAP+ astrocytes, and ∼5% Map2+ neurons as determined by
of four independent cultures. 40× magnification for (A), 200× magnification for (B), and
Fig. 2. JHMV replicates in glial-derived cell cultures. (A) Differentiated progenitor cultures were infected with JHMV and viral titers in supernatants determined at 12, 24, and 48 h
post-infection (p.i.) by plaque assay. Data are presented as average±SEM and represent two independent experiments. Immunocytochemical staining for viral antigen at 2SEM and
represent two independent experiments. Immunocytochemical staining for viral antigen at 2. 4 h p.i. revealed wide-spread distribution of virus throughout the cell culture (B, 100×
magnification) with extensive cytopathology as characterized by large areas of syncytia formation (C, 400× magnification). Expression of viral antigen was determined using mAb-
specific for the N protein of JHMV and visualized by immunoperoxidase staining.
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layer (Fig. 2B). In addition, JHMV infection resulted in cytopathic effects
by 24 h p.i. characterized by wide-spread syncytia formation (Fig. 2C).
These findings indicate that differentiated cells derived from neural
progenitors are susceptible to JHMV infection and are capable of
supporting replicating virus which results in extensive cytopathology.Fig. 3. IFN-γ inhibits viral replication in glial-derived cultures. (A) Differentiated progenitor
IFN-g (10 (100 U/ml). Viral titers were determined in culture supernatants at 12, 24, and 48
points examined. (B) Titration of IFN-γ revealed a concentration-dependent anti-viral effect w
100 or 10 U/ml. Viral titers were determined at 24 h p.i. (C) Pre-treatment of cultures with IFN
in viral titers at 24 h p.i. compared to cultures treatedwith IFN-γ at the time of infection. (D–F
formation (D, 100× magnification) and viral antigen detected in single cells (E, 200× magnifica
200× magnification). ⁎p≤0.05, ⁎⁎p≤0.001.IFN-γ suppresses JHMV replication in cultured OPC
Previous studies by Parra et al. (1999) demonstrated that IFN-γ has
an important role in controlling JHMV replication within oligoden-
drocytes of persistently infected mice. Therefore, we next determined
whether IFN-γ was capable of inhibiting JHMV replication followingcultures were infected with JHMV and subsequently treated with recombinant mouse
h p.i. IFN-γ-treated cultures had significantly (p≤0.05) reduced viral titers at all time
ith significant (p≤0.05) inhibition in viral replication occurring with IFN-γ treatment of
-γ (100 U/ml, 24 h) enhanced anti-viral effect as demonstrated by significant reduction
) Staining for viral antigen in IFN-γ-treated cultures at 24 h p.i. revealed limited syncytia
tion). In contrast, media controls exhibited extensive viral replication and syncytium (F,
Fig. 4. The IFN-γ-mediated antiviral effect is not dependent upon expression of CXCL9
or CXCL10. Expression of the non-ELR CXC chemokines CXCL9 (A) and CXCL10 (B) was
determined by ELISA at 12 and 24 h following either infection with JHMV alone or IFN-
g-treatment of infected cultures. JHMV infection did not result in detectable protein
levels for either CXCL9 or CXCL10. Treatment of infected cultures with IFN–treatment of
infected cultures. JHMV infection did not result in detectable protein levels for either
CXCL9 or CXCL10. Treatment of infected cultures with IFN-γ (100 U/ml) did result in
elevated levels of both CXCL9 and CXCL10. IFN-γ treatment of JHMV-infected cells
derived from either CXCL10−/− mice (C) or CXCR3−/− mice (D) resulted in significant
(⁎pb0.05) reduction in viral replication at 24 h p.i. Results shown in (A) and (B) are
representative of two independent experiments. Results in (C) and (D) are presented as
average±SEM and represent two independent experiments.
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treatment of JHMV-infected cells with recombinant mouse IFN-γ
inhibited viral replication at 12 (57% reduction, pb0.05), 24 (56%
reduction, pb0.05), and 48 h p.i. (94% reduction, pb0.05) compared to
media-treated controls. Moreover, the IFN-γ-mediated inhibition of
JHMV-replication was concentration-dependent; titration of IFN-γ
resulted in diminished antiviral effects (Fig. 3B). The pretreatment of
cultures with IFN-γ (100 U/ml) resulted in a significant (pb0.05)
reduction in viral titers at 24 h p.i. when compared to cultures
incubated with IFN-γ following infection (Fig. 3C). Immunocytochem-
istry revealed that IFN-γ treatment of differentiated neural progenitor
cultures limited the extensive cytopathic effects (Figs. 3D and E)Fig. 5. Type I IFN inhibits JHMV replication in differentiated glial cultures. (A) Type I IFNwasm
(100 U/ml) at 24 and 48 h p.i. No detectable IFN-α/βwas present in cultures infectedwith viru
post-treatment. IFN-γ treatment of JHMV-infected cultures resulted in increased IFN-α/βprod
of JHMV-infected cultures with either 100 U/ml of recombinant IFN-α or IFN-β diminished v
with IFN-β (value below limit of detection, b150 pfu/ml) compared to IFN-α (⁎pb0.05). (C) Gli
with virus and treated with IFN-γ (100 U/ml) and viral titers determined at 48 h p.i. IFN-γ tre
cultures at either time point. Data are presented as average±SEM and are representative ofobserved in untreated cells (Fig. 3F) as characterized by diminished
syncytium formation. Together these data indicate that IFN-γ
activates differentiated neural progenitors to inhibit JHMV replication,
which correlates with muted cytopathology.
IFN-γ-mediated suppression of JHMV replication is not dependent on
expression of non-ELR chemokines
It is known that IFN-γ is capable of inducing expression of the non-
ELR chemokines CXCL9 and CXCL10 in numerous cell types including
resident cells of the CNS such as astrocytes and microglia (Bhowmick
et al., 2007; Majumder et al., 1998; Vanguri and Farber, 1994).
Moreover, in vivo astrocytes have been shown to express CXCL9 and
CXCL10mRNA transcripts during the acute response to JHMV infection
and in vitro cultured astrocytes are capable of expressing CXCL10
mRNA transcripts (Lane et al., 1998; Liu et al., 2000, 2001). Neither
CXCL9 nor CXCL10 are detectable in differentiated neural progenitor
cultures in response to JHMV infection at 12 or 24 h p.i. (Figs. 4A
and B). In contrast, IFN-γ treatment of infected cultures resulted in
measurable levels of both CXCL9 and CXCL10 at 12 and 24 h p.i. (Figs.
4A and B). Levels of CXCL10 were dramatically higher (∼45,000 pg/ml
at 12 h) compared to CXCL9 levels (∼75 pg/ml at 12 h) suggesting
differential promoter sensitivities to IFN-γ treatment or altered
stability at either RNA or protein levels. To assess the importance of
IFN-γ-mediated production of CXCL9 and CXCL10 in the inhibition
of JHMV replication, neural progenitor cells were isolated from
CXCL10−/− mice and mice deficient in the signaling receptor for
CXCL9 and CXCL10, CXCR3 (CXCR3−/− mice). The neural progenitor
cells from deficient mice were differentiated in vitro, infected with
JHMV and treated with IFN-γ. As we observed inwildtype mice, such
treatment resulted in a significant reduction in viral titers at 24 h p.i.
compared to infected cells incubated with medium alone (Figs. 4C
and D). Therefore, the IFN-γ-mediated anti-viral effect observed
occurs independently of either production of CXCL9, and CXCL10 or
CXCR3 signaling.
IFN-α/β production following IFN-γ-treatment
Type I IFN (IFN α and β) exhibit potent antiviral activity and have
recently been shown to be important in controlling JHMV replication
in vivo (Ireland et al., 2008). Therefore, we next evaluated production
of type I IFN from differentiated progenitor cultures following JHMV
infection. As shown in Fig. 5A, JHMV infection did not result in
detectable levels of IFN-α/β at either 24 or 48 h p.i. However, IFN-γ
treatment of JHMV-infected cultures resulted in expression of IFN-α/βeasured in supernatants from cell cultures infectedwith JHMV and/or treatedwith IFN-γ
s alone yet IFN-γ treatment resulted in IFN-α/β production at 24 h that increased by 48 h
uction compared to IFN-γ treatment alone at both24 and 48h timepoints. (B) Treatment
iral replication compared to untreated cultures with a greater anti-viral effect observed
al cultureswere derived fromprogenitor cells obtained from type I IFNR−/−mice, infected
atment resulted in a reduction (⁎pb0.05) in viral titers when compared tomedia control
two independent experiments.
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Further, direct treatment with either recombinant mouse IFN-α or
IFN-β of JHMV-infected cultures resulted in a dramatic reduction in
viral replication compared to media treatment (Fig. 5B). IFN-β
exhibited ∼90% greater reduction in viral replication compared to
IFN-α treatment indicating a more potent antiviral activity associated
with IFN-β signaling (Fig. 5B). Next, progenitor derived glial cultures
were generated from type I IFN receptor-deficient mice (IFN-R−/−)
mice and treated with IFN-γ following JHMV infection. As shown in
Fig. 5C, such treatment did result in a reduction in viral replication
(pb0.05) compared to media-treated controls by 48 h p.i. However,
viral replicationwas reduced, on average, by only 53% in IFN-R−/− cells
compared to N90% reduction in wildtype cells (Figs. 3A and C).
Therefore, these data indicate that the IFN-γ-mediated antiviral effect
is diminished in the absence of type I IFN signaling indicating that one
mechanism by which IFN-γ promotes control of JHMV replication
within glial-derived progenitors is through induction of type I IFN.
Discussion
The findings put forth in this paper provide, to our knowledge, the
first demonstration that JHMV is capable of infecting and replicating
within primary cultures of glia derived from neural progenitor cells.
These findings are distinct from earlier studies (Dubois-Dalcq et al.,
1982; Lavi et al., 1987; Rempel et al., 2005) showing that primary
neural cultures are susceptible to viral infection, as we have allowed
for differentiation of glial cells from neural progenitor cells into
defined glia populations. In addition, we have demonstrated that IFN-
γ treatment of JHMV-infected cultures suppresses JHMV replication
and this is dependent, in part, on secretion of IFN-I. The importance of
IFN-I in defense following viral infection of the CNS has been
documented in several animal models. Infection of mice in which
IFN-I is genetically silenced or signaling blocked results in uncon-
trolled proliferation of West Nile virus (Samuel and Diamond, 2005),
Sindbis virus (Burdeinick-Kerr et al., 2007; Byrnes et al., 2000), and
Semliki forest virus (Fragkoudis et al., 2007). The cellular source of
IFN-I production is controlled by viral tropism and the model system
employed. For example, neurons are a primary source of IFN-I in
response to West Nile virus infection and these cells also represent a
prominent cellular target for viral infection and replication (Samuel
and Diamond, 2005). Similarly, robust cytokine production, including
IFN-β, is observed following infection of astrocyte cultures with
Theiler's murine encephalomyelitis virus (TMEV) (Palma et al., 2003).
In the case of JHMV infection, emerging evidence highlights the
importance of IFN-I in protection of the CNS in response to infection.
Bergmann and colleagues (Ireland et al., 2008) recently demonstrated
increased mortality correlating with wide-spread JHMV dissemina-
tion throughout the parenchyma including expanded cell tropism
with neurons infected in mice deficient in IFN-I receptor (IFNR−/−).
Additional support for an important role for IFN-I in host defense in
response to infection with mouse coronaviruses are derived from
studies that demonstrate increased disease severity following anti-IFN
antibody treatment (Lavi and Wang, 1995) and enhanced resistance
following treatment with recombinant IFN-β (Matsuyama et al., 2000;
Smith et al, 1987).
Further support for mouse coronaviruses in initiating IFN-I
production following experimental infection of mice are provided by
studies from Cervantes-Barragan et al. (2007) indicating that periph-
eral infectionwith a hepatotropic strain of MHV (MHV-A59) results in
increased IFN-I production by plasmacytoid dendritic cells. While it is
clear that IFN-I is produced in vivo in response to mouse coronavirus
infection and participates in effective host defense, the molecular
signals regulating expression on a cellular basis are less well
characterized. Indeed, IFN-β is not produced in response to JHMV
infection of fibroblasts but this is not dependent on the absence of
intracellular double-stranded RNA or deficiencies in IFN-β signaling(Roth-Cross et al., 2007). Impaired IFN-β production within JHMV-
infected cultures correlated with impaired translocation of transcrip-
tion factors IRF-3 and IRF-7 into the nucleus of infection cells (Versteeg
et al., 2007; Zhou and Perlman, 2007). In addition, it may be possible
that double-stranded RNA generated during the course of JHMV
infection is not accessible to cellular pattern recognition receptors
(PPR) such as RIG-I,Mda-5, andTLR-3 (Zhou andPerlman, 2007).While
themolecularmechanisms associatedwith inhibited IFN-β production
have not been completely defined, the MHV nucleocapsid protein has
been suggested to be an IFN-I antagonist (Ye et al., 2007).
Data provided in the current study demonstrate that JHMV
infection of differentiated progenitor cells resulted in muted expres-
sion of IFN-I and virus was able to replicate in an unrestricted manner.
In addition, secretion of CXCL9 and CXCL10 was also impaired
following JHMV infection of differentiated progenitor cultures and
this is in contrast to previous findings indicating robust chemokine
expression following infection of primary cultures of astrocytes. These
results support the earlier hypothesis that within certain host cell
populations, double-stranded RNA generated during the course of
JHMV replication may not be accessible to PPR and this impacts
secretion of IFN-I and non-ELR chemokines CXCL9 and CXCL10.
Moreover, since the majority of progenitor cells (∼70–80%) differ-
entiate into oligodendrocyte progenitor cells (OPC), it is possible that
oligodendrocytes are unable to synthesize either CXCL9 or CXCL10 in
response to JHMV infection.
Treatment of progenitor cultures with IFN-γ resulted in reduced
JHMV replication and this highlights the importance of this cytokine
in host defense following JHMV infection. Additionally, these data
support and extend studies by Stohlman and colleagues (Gonzalez
et al., 2005, 2006; Parra et al., 1999) that have demonstrated IFN-γ is
critical in controlling JHMV replication in oligodendrocytes in vivo.
Infection of IFN-γ−/− mice with JHMV highlighted a critical role for
this cytokine in controlling viral replication within oligodendrocytes
(Parra et al., 1999). Additionally, transgenic mice expressing a
dominant-negative IFN-γ-receptor specifically on oligodendroglia
demonstrated that IFN-γ is required for inhibiting viral replication
(Gonzalez et al., 2005, 2006). The findings put forth in the present
study clearly indicate that IFN-γ suppresses JHMV replication in
glial-committed progenitor cells derived from neural precursors.
Moreover, the IFN-γ-mediated antiviral effect is not dependent
on secretion of CXCR3-binding chemokines. Although the in vivo
mechanism(s) by which IFN-γ evokes an antiviral response have not
yet been defined, our data suggest that production of IFN-I by IFN-γ-
treated glia may contribute to viral control. Further support for type
I IFN in controlling JHMV replication within oligodendrocyte-
enriched cultures is provided by the demonstration that treatment
of JHMV-infected oligodendrocytes with either recombinant IFN-α
or IFN-β resulted in N1 log decrease in viral titers with IFN-β having
a much greater anti-viral effect compared to IFN-α in controlling
replication.
Neurotropic viruses are capable of infecting and replicating within
OPC (Dietrich et al., 2004; Levine et al., 1998; Mock et al., 2006). For
example, human herpesvirus 6 (HHV6) is capable of infecting and
replicating within the human oligodendrocytes and suggested to be
involved in the pathogenesis of both acute and chronic inflammatory
demyelinating diseases (Dietrich et al., 2004; Mock et al., 2006). HHV6
infection of human OPC cultures results in formation of multi-
nucleated syncytia and elevated expression of GalC (Dietrich et al.,
2004). OPC proliferation was also impaired in HHV6-infected cultures
and infected cells and suggests that infection in vivo may have long-
lasting effects on precursor cell properties. These findings are
interesting in that remyelination is relatively slow in JHMV-infected
mice yet OPC are present within and surrounding areas of on-going
demyelination. This suggests that the ability of OPC to successfully
remyelinate axons is impaired and/or an environment that is
conducive for promoting remyelination is not available. Having
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primary cultures of OPC indicates that these cells are susceptible to
infection in vivo. Therefore, it is interesting to speculate that early
infection of neural progenitor cells impacts either generation of OPC
and/or the ability of OPC to successfully remyelinate demyelinated
axons at later stages of infection. We are currently addressing these
possibilities.
Materials and methods
Virus and mice
The neurotropic strain JHMV (2.2V-1) of mouse hepatitis virus
(MHV) was used for all experiments described here (Fleming et al.,
1986). Wild type mice for progenitor cell isolation, C57BL/6 mice (on
the H-2b background), were purchased from the National Cancer
Institute (Frederick, MD). Additionalmouse strains used for progenitor
cultures, CXCL10−/−, CXCR3−/−, and IFN-I receptor deficient (IFNAR−/−)
(C57BL/6 H-2b background), were bred in the University of California,
Irvine animal facility. The animal protocols and procedures used for
these studies were reviewed and approved by the Institutional Animal
Care and Use Committee of the University of California, Irvine.
Neural progenitor cultures
Neural progenitor cells were cultured as previously described
(Totoiu et al., 2004). In brief, striata from 5 to 6 postnatal day 1 mice
were dissected, triturated and dissociated in 0.05% Trypsin-EDTA. The
resulting single cell suspension was cultured for 6–7 days in 25 ml
serum free media (DMEM:F12 supplemented with B27 supplement,
1× Insulin–Transferrin–Selenium-X Supplement, 1× Penicillin–Strep-
tomycin and T3) with 20 ng/ml human recombinant epidermal
growth factor (EGF; Sigma-Aldrich) (Ben-Hur et al., 1998). Media was
replaced on days 1, 3, and 5; culture supernatant and floating clusters
were removed, centrifuged at 300 ×g for 5 min and resuspended in
fresh media with EGF. After one week, cells had proliferated into
numerous free-floating spheres.
Adhesion and differentiation of cell spheres
After one week, cell spheres were transferred to matrigel (BD
Bioscience, Bedford, MA) coated flasks (use thin coat method, 1:30
dilution) at a low density. Individual cells spread out from the
attached spheres and formed a monolayer with 1 to 2 days. Once the
monolayer formed, cells were trypsinized, counted and plated into
four chamber imaging slides (Nalgene-Nunc International, Rochester,
NY), 6-well plates or T25 flask (Costar, Corning, NY) previously coated
with matrigel (BD Biosciences). Cells were allowed to equilibrate for
an additional 1–2 days before viral infection or staining procedures
were done.
Viral infection and viral titer assay
For all experiments shown, JHMV was added to cultures at a
multiplicity of infection (MOI) of 0.1 pfu/cell. Virus was allowed to
adsorb for 1 h, cultures were washed with PBS and replaced with 4 ml
of fresh medium. Recombinant mouse IFN-γ, IFN-α, and IFN-β
cytokines were purchased from Cell Sciences (Canton, MA). Viral
titers in supernatants of infected cultures were determined on DBT
astrocytoma cells at defined time points post-infection (p.i.) (Hirano
et al., 1978; Lane et al., 2000).
Immunofluorescence
To assess differentiation potential, cells were grown on matrigel
coated imaging slides for a total of 4 days, fixed in 4% paraformalde-hyde (Fisher Scientific, Fair Lawn, NJ) for 20 min and immunofluor-
escence staining was performed using standard protocols. Imaging
chambers were blocked with 10% normal goat serum (NGS) (Vector
Laboratories, Burlingame, CA) for 1 h at room temperature. Primary
antibodies (polyclonal rabbit anti-GalC, Chemicon, 1:100 dilution in
10% NGS; monoclonal mouse anti-Map2, Sigma, 1:750 dilution in 10%
NGS; polyclonal rabbit anti-GFAP, Invitrogen, 1:500 dilution in 10%
NGS) or blocking solution (negative control, 10% NGS in PBS) were
applied to chambers overnight at 4 °C on rocker. Slides were rinsed
three times with PBS and fluorescent-conjugated secondary antibody
(Alexa 594, goat anti-rabbit or goat anti-mouse IgG H+L, 1:400
dilution in 10% NGS; Invitrogen) was applied and incubated for
30 min at room temperature. Slides were rinsed three times in PBS,
and nuclear staining was with Hoechst 33342 (1 μg/ml in PBS,
Molecular Probes, Eugene, OR) for 10 min. Cell quantification was
conducted using an Olympus BX-60 microscope, 200× magnification.
The percentage of immunopositive cells was determined by dividing
the total number of immunopositive cells by the total number of
Hoechst-positive cells in five images from each chamber, and
averaging the results from three different chambers per marker.
Each 4-chamber imaging slide had one no-primary control chamber
and three stained chambers for each of the markers mentioned above.
Only immunopositive cells with a Hoechst-positive nucleus were
counted.
Immunocytochemistry
Distribution of viral antigen in cultures was determined by
immunoperoxidase staining, as specified by the manufacturer
(Vectastain-ABC kit and DAB peroxidase substrate kit; Vector
Laboratories). Imaging chambers were blocked with triton contain-
ing blocking buffer (BB), (0.3% Triton X-100 and 10% NGS normal goat
serum in PBS), for 1 h at room temperature. The anti-JHMVmAb J.3.3
(1:20 dilution in BB) specific for the carboxyl terminus of the viral
nucleocapsid (N) protein was applied and incubated overnight at
4ϒC. Slides were rinsed three times in PBS and secondary antibody
(biotinylated goat-anti-mouse IgG H+L, Vector Laboratories, 1:750
dilution in BB) was applied and incubated for 1.5 h at room
temperature. Slides were rinsed three times in PBS and counter-
stained with hematoxylin (Bergmann et al., 2003; Fleming et al.,
1983; Walsh et al., 2007).
Interferon bioassay
Differentiated neural progenitor cells were infected withMHV, and
levels of IFN were measured using a bioassay based on inhibition of
VSV growth in L929 cells. Supernatants were harvested and exposed
to UV light to inactivate infectious virus. L929 cells infected with
1000 pfu VSV were treated with dilutions of supernatants or
recombinant murine IFN-β (PBL Biomedical Laboratories, Piscataway,
NJ) at 30 min post-infection (p.i.). Titers of VSV were determined on
Vero cells. IFN levels were calculated based on standard curves
generated with recombinant IFN-β.
ELISA
OPC culture supernatants were used to measure chemokines
CXCL9 and CXCL10. ELISAs were performed using the Duoset Mouse
CXCL9 and CXCL10 ELISA kit (R & D Systems, Minneapolis, MN), as
specified by the manufacturer.
Statistical analysis
Statistically significant differences between groups of mice were
determined by Student's t test and p values of b0.05 were considered
significant.
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